---
layout: post
title: "华特达因：子公司注射用盐酸石蒜碱硫酯临床试验获批"
date: 2022-01-10 16:07:51 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.000915" data-code="000915|0|2" data-code2="000915|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.000915&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 000915_0" data-code="K 000915|0|2" data-code2="K 000915|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>华特达因(000915)1月10日晚间公告，公司子公司达因药业注射用盐酸石蒜碱硫酯获得药物临床批准通知书。该药品拟用于儿童手足口病的治疗。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201102242158692>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)